The outcome of children with acute myeloid leukemia (AML) post‐allogeneic stem cell transplantation (SCT) is not improved by the addition of etoposide to the conditioning regimen

Relapse remains a concern for children with AML undergoing allogeneic SCT, so in an effort to reduce the risk of relapse in these patients, we intensified our pre‐SCT preparation by adding etoposide to the standard busulfan and cyclophosphamide regimen.

[1]  J. Byrd,et al.  High-dose busulfan, cyclophosphamide, and etoposide does not improve outcome of allogeneic stem cell transplantation compared to BuCy2 in patients with acute myeloid leukemia , 2005, Bone Marrow Transplantation.

[2]  H. Dombret,et al.  Allogeneic bone marrow transplantation for acute myeloblastic leukaemia in remission: risk factors for long-term morbidity and mortality , 2003, Bone Marrow Transplantation.

[3]  C. Felix.  Leukemias related to treatment with DNA topoisomerase II inhibitors. , 2001, Medical and pediatric oncology.

[4]  M. Coppes,et al.  Hematopoietic stem cell transplantation (HSCT) with a conditioning regimen of busulfan, cyclophosphamide, and etoposide for children with acute myelogenous leukemia (AML): a phase I study of the Pediatric Blood and Marrow Transplant Consortium. , 2000, Medical and pediatric oncology.

[5]  N. Kröger,et al.  Dose-dependent effect of etoposide in combination with busulfan plus cyclophosphamide as conditioning for stem cell transplantation in patients with acute myeloid leukemia , 2000, Bone Marrow Transplantation.

[6]  M. Horowitz,et al.  Effect of postremission chemotherapy before human leukocyte antigen-identical sibling transplantation for acute myelogenous leukemia in first complete remission. , 2000, Blood.

[7]  J. Sierra,et al.  No impact of high‐dose cytarabine on the outcome of patients transplanted for acute myeloblastic leukaemia in first remission , 2000, British journal of haematology.

[8]  N. Kröger,et al.  High dose chemotherapy with busulfan, cyclophosphamide, and etoposide as conditioning regimen for allogeneic bone marrow transplantation for patients with acute myeloid leukemia in first complete remission. , 1997, Clinical cancer research : an official journal of the American Association for Cancer Research.

[9]  J. Krischer,et al.  Autologous bone marrow transplantation versus intensive consolidation chemotherapy for acute myeloid leukemia in childhood , 1996 .

[10]  Y. Kanda,et al.  Etoposide with/without G‐CSF with busulfan and cyclophosphamide as conditioning for bone marrow transplantation , 1996, American journal of hematology.

[11]  A. Baruchel,et al.  Allogeneic bone marrow transplantation vs aggressive post-remission chemotherapy for children with acute myeloid leukemia in first complete remission. A prospective study from the French Society of Pediatric Hematology and Immunology (SHIP). , 1996, Bone marrow transplantation.

[12]  F. Mandelli,et al.  Autologous or allogeneic bone marrow transplantation compared with intensive chemotherapy in acute myelogenous leukemia. European Organization for Research and Treatment of Cancer (EORTC) and the Gruppo Italiano Malattie Ematologiche Maligne dell'Adulto (GIMEMA) Leukemia Cooperative Groups. , 1995, The New England journal of medicine.

[13]  F. Mandelli,et al.  Prospective comparative study of bone marrow transplantation and postremission chemotherapy for childhood acute myelogenous leukemia. The Associazione Italiana Ematologia ed Oncologia Pediatrica Cooperative Group. , 1993, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[14]  F. Appelbaum,et al.  Allogeneic marrow transplantation in patients with chronic myeloid leukemia in the chronic phase: a randomized trial of two irradiation regimens. , 1991, Blood.

[15]  F. Appelbaum,et al.  Allogeneic marrow transplantation in patients with acute myeloid leukemia in first remission: a randomized trial of two irradiation regimens. , 1990, Blood.

[16]  J. Klein,et al.  Bone marrow transplantation for leukemia following a new busulfan and cyclophosphamide regimen , 1987 .

[17]  J. Doroshow,et al.  Total body irradiation and high-dose etoposide: a new preparatory regimen for bone marrow transplantation in patients with advanced hematologic malignancies [published erratum appears in Blood 1987 Jun;69(6):1789] , 1987 .

[18]  T. Chou,et al.  Synergistic effect of 4-hydroperoxycyclophosphamide and etoposide on a human promyelocytic leukemia cell line (HL-60) demonstrated by computer analysis. , 1985, Cancer research.

[19]  M. Kanje,et al.  Effect of estramustine phosphate on the assembly of isolated bovine brain microtubules and fast axonal transport in the frog sciatic nerve. , 1985, Cancer research.

[20]  R. Brookmeyer,et al.  Marrow transplantation for acute nonlymphocytic leukemia after treatment with busulfan and cyclophosphamide. , 1983, The New England journal of medicine.

[21]  J. Buckley,et al.  A comparison of allogeneic bone marrow transplantation, autologous bone marrow transplantation, and aggressive chemotherapy in children with acute myeloid leukemia in remission. , 2001, Blood.

[22]  J. DiPersio,et al.  Allogeneic bone marrow transplantation for children with acute leukemia: cytoreduction with fractionated total body irradiation, high-dose etoposide and cyclophosphamide , 2000, Bone Marrow Transplantation.

[23]  J. Blatt,et al.  Etoposide and Langerhans cell histiocytosis: second malignancies, a second look. , 1999, Pediatric hematology and oncology.

[24]  I. Bernstein,et al.  Chemotherapy for induction of remission of childhood acute myeloid leukemia followed by marrow transplantation or multiagent chemotherapy: a report from the Childrens Cancer Group. , 1994, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[25]  Eileen,et al.  Fractionated total body irradiation and high-dose etoposide as a preparatory regimen for bone marrow transplantation for 99 patients with acute leukemia in first complete remission. , 1993, Blood.

[26]  H. Rugo,et al.  Autologous bone marrow transplantation for acute myeloid leukemia using busulfan plus etoposide as a preparative regimen. , 1993, Blood.

[27]  R. Gale,et al.  Etoposide in leukemia, lymphoma and bone marrow transplantation. , 1989, Leukemia research.